In today’s briefing:
- Mankind Pharma IPO- Forensic Analysis
- Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential
- Coeptistx (COEP) Deverra Deal Flash Note 20042023
Mankind Pharma IPO- Forensic Analysis
- Mankind Pharma (6596876Z IN)‘s IPO is lined up to be open for subscription next week.
- Mankind is one of the largest pharmaceutical formulation player in India. The company is a market leader in condoms, pregnancy test kits, emergency contraceptives category, etc.
- However, when it comes to the balance sheet, there are several aspects that warrant attention. These include acquisitions, asset quality, non-comparable return ratios owing to accounting treatment, etc.
Dechra Pharmaceuticals (DPH LN): Best Case Scenario Offers 10% Upside Potential
- Dechra Pharmaceuticals (DPH LN) received an offer from the Swedish private equity firm EQT regarding a possible all-cash deal, where Dechra shareholders would receive £40.70 per ordinary share in cash.
- Right after the announcement, Dechra shares surged 33%. The shares are currently trading at £37.66, implying 10% upside potential.
- Without EQT offer, based on current financial performance, Dechra has a bleak outlook. Currently, Dechra has average target price of £39.39, implying a spread of just ~5%.
Coeptistx (COEP) Deverra Deal Flash Note 20042023
- Binding exclusivity to acquire or license Deverra Therapeutics’ platform asset
- CAR-T + GEAR COEP platforms could plug into Deverra platform
- Other key assets – 2x FDA approved PI INDs for CD34+ NK Cells.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
